JP7250814B2 - 新規ｇｌｐ－１類似体 - Google Patents

新規ｇｌｐ－１類似体 Download PDF

Info

Publication number
JP7250814B2
JP7250814B2 JP2020553627A JP2020553627A JP7250814B2 JP 7250814 B2 JP7250814 B2 JP 7250814B2 JP 2020553627 A JP2020553627 A JP 2020553627A JP 2020553627 A JP2020553627 A JP 2020553627A JP 7250814 B2 JP7250814 B2 JP 7250814B2
Authority
JP
Japan
Prior art keywords
amino
group
ethoxy
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020553627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520346A (ja
Inventor
テナッティ，ラジャマンナル
チャトゥルヴェーディー，ニシス
ブラーデ，ヴィノード・サンパトラオ
シャヒ，プラディープ・ディネシュ
ナタラジャン，ムツクマラン
ナガラジャ，ラビシャンカラ・マダバティ
ザラワディア，リシ・マンスクラル
パンディア，クナル
パテル，ブリエッシュクマール
ジョシー，ディレン・ラメシュチャンドラ
ソニー，クルナル・ハリシュバイ
ティワーリー，アビシェーク
パテル，ヴィプルクマール・シャンカルバイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2021520346A publication Critical patent/JP2021520346A/ja
Priority to JP2023045498A priority Critical patent/JP2023078367A/ja
Application granted granted Critical
Publication of JP7250814B2 publication Critical patent/JP7250814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)
JP2020553627A 2018-04-05 2019-04-05 新規ｇｌｐ－１類似体 Active JP7250814B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045498A JP2023078367A (ja) 2018-04-05 2023-03-22 新規ｇｌｐ－１類似体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821013109 2018-04-05
IN201821040468 2018-10-26
IN201821040474 2018-10-26
IN201821040474 2018-10-26
IN201821040468 2018-10-26
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045498A Division JP2023078367A (ja) 2018-04-05 2023-03-22 新規ｇｌｐ－１類似体

Publications (2)

Publication Number Publication Date
JP2021520346A JP2021520346A (ja) 2021-08-19
JP7250814B2 true JP7250814B2 (ja) 2023-04-03

Family

ID=66589592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020553627A Active JP7250814B2 (ja) 2018-04-05 2019-04-05 新規ｇｌｐ－１類似体
JP2023045498A Pending JP2023078367A (ja) 2018-04-05 2023-03-22 新規ｇｌｐ－１類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045498A Pending JP2023078367A (ja) 2018-04-05 2023-03-22 新規ｇｌｐ－１類似体

Country Status (33)

Country Link
US (7) US11447535B2 (https=)
EP (3) EP4364751A3 (https=)
JP (2) JP7250814B2 (https=)
KR (2) KR20250065720A (https=)
CN (3) CN117964735A (https=)
AU (3) AU2019247936C1 (https=)
BR (1) BR112020020419A2 (https=)
CA (1) CA3095988A1 (https=)
CL (1) CL2020002574A1 (https=)
CO (1) CO2020012425A2 (https=)
CY (1) CY1125528T1 (https=)
DK (2) DK3774862T3 (https=)
EC (1) ECSP20070185A (https=)
ES (2) ES2925678T3 (https=)
FI (1) FI4122954T3 (https=)
HR (2) HRP20240749T1 (https=)
HU (2) HUE060135T2 (https=)
IL (1) IL277483B1 (https=)
JO (1) JOP20200251B1 (https=)
LT (2) LT3774862T (https=)
MX (2) MX2020010505A (https=)
MY (1) MY202560A (https=)
PE (1) PE20211417A1 (https=)
PH (1) PH12020551591A1 (https=)
PL (2) PL4122954T3 (https=)
PT (2) PT4122954T (https=)
RS (2) RS65639B1 (https=)
SG (1) SG11202009467YA (https=)
SI (2) SI3774862T1 (https=)
SM (2) SMT202400241T1 (https=)
UA (1) UA128210C2 (https=)
WO (1) WO2019193576A1 (https=)
ZA (1) ZA202306729B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
PE20231309A1 (es) * 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
AU2022386166A1 (en) 2021-11-10 2024-06-20 I2O Therapeutics, Inc. Ionic liquid compositions
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
EP4731244A1 (en) 2023-06-20 2026-04-29 Sun Pharmaceutical Industries Limited Glp-1 analog for use in the treatment of metabolic disorders
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097537A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Acylated glp-1 compounds
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
WO2018178796A1 (en) 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
EP1056774A1 (en) 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2003200839B2 (en) 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
JPWO2004037859A1 (ja) 2002-10-11 2006-02-23 株式会社三和化学研究所 Ｇｌｐ−１誘導体及びその経粘膜吸収型製剤
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
ATE549028T1 (de) 2003-05-15 2012-03-15 Tufts College Stabile analoga von glp-1
BR122019021416A2 (https=) 2003-09-19 2019-12-21
JP2007536214A (ja) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１類似体
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
CA2607566A1 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US8318668B2 (en) 2005-09-08 2012-11-27 Trustees Of Tufts College Stabilized GLP-1 analogs
DE602005017628D1 (de) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
AU2011247824B2 (en) 2010-04-27 2014-02-13 Betta Pharmaceuticals Co., Ltd Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
JP6039569B2 (ja) 2010-11-09 2016-12-07 ノヴォ ノルディスク アー／エス 二重アシル化されたｇｌｐ−１誘導体
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
EP3016975B1 (en) 2013-07-04 2019-01-16 Novo Nordisk A/S Derivatives of glp-1 like peptides, and uses thereof
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
PL3057984T3 (pl) * 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
CN105849123A (zh) 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
JP6730278B2 (ja) 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
WO2017035432A1 (en) 2015-08-26 2017-03-02 Robert Doyle Coagonists of glucagon-like peptide 1 receptor and neuropeptide y2 receptor
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
MX2018014966A (es) 2016-06-09 2019-08-14 Medimmune Ltd Peptidos monolipidados resistentes a proteasas.
ES2828526T3 (es) 2016-11-07 2021-05-26 Novo Nordisk As Esteres activos DCHBS de compuestos PEG y sus usos
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
JP2021516556A (ja) 2018-03-09 2021-07-08 エンザイペプ ビー．ブイ． リラグルチド、セマグルチド及びｇｌｐ−１の化学酵素合成
MX2020010505A (es) * 2018-04-05 2021-01-15 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097537A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Acylated glp-1 compounds
WO2006097538A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
WO2018178796A1 (en) 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain

Also Published As

Publication number Publication date
RS65639B1 (sr) 2024-07-31
JOP20200251A1 (ar) 2020-10-04
BR112020020419A2 (pt) 2021-01-19
CN112236444A (zh) 2021-01-15
EP3774862A1 (en) 2021-02-17
JP2023078367A (ja) 2023-06-06
PT3774862T (pt) 2022-09-05
SMT202200352T1 (it) 2022-09-14
EP4122954B1 (en) 2024-04-03
RS63523B1 (sr) 2022-09-30
PT4122954T (pt) 2024-06-05
CN120554480A (zh) 2025-08-29
US20220402992A1 (en) 2022-12-22
ZA202306729B (en) 2024-03-27
CL2020002574A1 (es) 2021-06-04
US20240199718A1 (en) 2024-06-20
US11866477B2 (en) 2024-01-09
AU2019247936B2 (en) 2023-03-02
MY202560A (en) 2024-05-08
SG11202009467YA (en) 2020-10-29
SI4122954T1 (sl) 2024-07-31
AU2023203430B2 (en) 2025-07-03
KR20200141469A (ko) 2020-12-18
JP2021520346A (ja) 2021-08-19
US20240376175A1 (en) 2024-11-14
US20200362007A1 (en) 2020-11-19
AU2019247936C1 (en) 2023-06-15
KR20250065720A (ko) 2025-05-13
EP4122954A1 (en) 2023-01-25
KR102801994B1 (ko) 2025-04-30
CN117964735A (zh) 2024-05-03
CN112236444B (zh) 2025-09-19
PH12020551591A1 (en) 2021-08-16
HUE067499T2 (hu) 2024-10-28
FI4122954T3 (fi) 2024-06-18
IL277483B1 (en) 2026-01-01
US11447535B2 (en) 2022-09-20
UA128210C2 (uk) 2024-05-08
WO2019193576A1 (en) 2019-10-10
PL4122954T3 (pl) 2024-08-12
MX2020010505A (es) 2021-01-15
CO2020012425A2 (es) 2020-12-21
ES2980707T3 (es) 2024-10-02
JOP20200251B1 (ar) 2024-04-18
IL277483A (en) 2020-11-30
HRP20240749T1 (hr) 2024-09-13
NZ768446A (en) 2025-10-31
AU2023203430A1 (en) 2023-06-29
EP3774862B1 (en) 2022-06-08
CA3095988A1 (en) 2019-10-10
LT3774862T (lt) 2022-09-12
DK4122954T3 (da) 2024-06-10
AU2019247936A1 (en) 2020-10-15
MX2024007688A (es) 2024-07-09
SI3774862T1 (sl) 2022-10-28
US11242373B2 (en) 2022-02-08
ES2925678T3 (es) 2022-10-19
PL3774862T3 (pl) 2022-10-03
PE20211417A1 (es) 2021-08-02
AU2025242190A1 (en) 2025-10-23
ECSP20070185A (es) 2021-01-29
CY1125528T1 (el) 2026-02-25
US11873328B2 (en) 2024-01-16
US12421289B2 (en) 2025-09-23
EP4364751A2 (en) 2024-05-08
LT4122954T (lt) 2024-06-25
US11485766B2 (en) 2022-11-01
US20190309040A1 (en) 2019-10-10
US20210206823A1 (en) 2021-07-08
SMT202400241T1 (it) 2024-07-09
HRP20221054T1 (hr) 2022-11-11
HUE060135T2 (hu) 2023-02-28
DK3774862T3 (da) 2022-09-05
US20220402991A1 (en) 2022-12-22
EP4364751A3 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP7250814B2 (ja) 新規ｇｌｐ－１類似体
CN106928341B (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
HK40086836A (en) Novel glp-1 analogues
HK40086836B (en) Novel glp-1 analogues
HK40103760A (en) Novel glp-1 analogues
EA049274B1 (ru) Новые аналоги glp-1
HK40044876A (en) Novel glp-1 analogues
HK40044876B (en) Novel glp-1 analogues
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
KR20260022948A (ko) Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250814

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250